The uncertainty of being or not infected with Covid-19 and the shortage of medicines in the health sector, mainly, have forced the population to fill prescriptions in private pharmacies and also to go to their offices, which is boosting sales of generic drugs.
This impulse has already achieved that in the first half of 2022, the percentage of income from generics exceeds that of patent medicines for the first time.
In the first half of 2021, generics had 49.3 percent of total revenue in the Mexican market -compared to 50.7 percent of patent medicines-, but in the same period of the current year they reached 51.5 percent. percent, revealed an analysis by the specialized firm IQVIA.
Arturo Manríquez, general director of the National Association of Generic Drug Distributors and Laboratories (Dilameg), said that IQVIA prepared this study for them, which includes the public health sector, hospitals and pharmacy chains, both supermarket and independent.
9 OUT OF 10 HAVE GENERIC
Although they did not consider Farmacias Similares in the diagnosis, Manríquez specified that they are clients of Dilameg, so the percentages largely reflect the growth of sales in the private market, that is, of pharmacies.
Much of the sale of private pharmacies are generics, since most have their own brands, although they also sell those of the laboratories.
“But the generic brand is the one that has grown the most, since various companies have them, such as Farmacias Benavides; those of Femsa, such as the IZAs; Savings Pharmacies; Las Guadalajara, even in pharmacies generic brands of laboratories are also sold”.
In addition, he highlighted, 9 out of 10 patent medicines already have a generic version.